- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 77.07%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 0.06 | 20.0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2024 (4) | 0.05 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (3) | -0.11 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | -0.27 | -800.0 | -35.0 | -0.26 | -550.0 | -18.18 | -0.27 | -550.0 | -35.0 |
| 25Q4 (7) | -0.03 | -110.0 | -200.0 | -0.04 | -115.38 | 0.0 | 0.06 | -25.0 | 20.0 |
| 25Q3 (6) | 0.30 | 1600.0 | -9.09 | 0.26 | 550.0 | -13.33 | 0.08 | 136.36 | 33.33 |
| 25Q2 (5) | -0.02 | 90.0 | 0.0 | 0.04 | 118.18 | 200.0 | -0.22 | -10.0 | 18.52 |
| 25Q1 (4) | -0.20 | -1900.0 | 0.0 | -0.22 | -450.0 | 0.0 | -0.20 | -500.0 | 0.0 |
| 24Q4 (3) | -0.01 | -103.03 | 0.0 | -0.04 | -113.33 | 0.0 | 0.05 | -16.67 | 0.0 |
| 24Q3 (2) | 0.33 | 1750.0 | 0.0 | 0.30 | 850.0 | 0.0 | 0.06 | 122.22 | 0.0 |
| 24Q2 (1) | -0.02 | 0.0 | 0.0 | -0.04 | 0.0 | 0.0 | -0.27 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.31 | 7.07 | 25.54 | 1.15 | 11.85 | 0.86 | N/A | - | ||
| 2026/3 | 0.29 | 10.72 | 0.92 | 0.84 | 7.54 | 0.84 | 0.55 | - | ||
| 2026/2 | 0.26 | -10.47 | -2.91 | 0.55 | 11.36 | 0.91 | 0.51 | - | ||
| 2026/1 | 0.29 | -18.64 | 28.24 | 0.29 | 28.24 | 0.99 | 0.47 | - | ||
| 2025/12 | 0.36 | 4.53 | 7.31 | 3.76 | 16.46 | 0.98 | 0.4 | - | ||
| 2025/11 | 0.34 | 22.88 | 15.59 | 3.4 | 17.51 | 0.92 | 0.43 | - | ||
| 2025/10 | 0.28 | -6.59 | 11.51 | 3.06 | 17.73 | 1.04 | 0.37 | - | ||
| 2025/9 | 0.3 | -36.65 | 28.94 | 2.78 | 18.39 | 1.1 | 0.35 | - | ||
| 2025/8 | 0.47 | 40.3 | 93.97 | 2.48 | 17.24 | 1.14 | 0.33 | 客戶需求增加，主係因癌症檢測及儀器銷售增加所致 | ||
| 2025/7 | 0.33 | 0.61 | -22.61 | 2.01 | 7.35 | 0.99 | 0.38 | - | ||
| 2025/6 | 0.33 | 2.8 | 43.67 | 1.68 | 16.32 | 0.9 | 0.48 | - | ||
| 2025/5 | 0.32 | 31.78 | -2.85 | 1.35 | 11.1 | 0.85 | 0.5 | - | ||
| 2025/4 | 0.25 | -13.92 | 25.26 | 1.02 | 16.38 | 0.8 | 0.54 | - | ||
| 2025/3 | 0.29 | 6.51 | 28.26 | 0.78 | 13.84 | 0.78 | 0.49 | - | ||
| 2025/2 | 0.27 | 18.26 | 32.58 | 0.49 | 6.9 | 0.83 | 0.46 | - | ||
| 2025/1 | 0.23 | -31.92 | -13.01 | 0.23 | -13.01 | 0.85 | 0.45 | - | ||
| 2024/12 | 0.33 | 12.6 | 24.09 | 3.23 | 14.97 | 0.88 | 0.42 | - | ||
| 2024/11 | 0.3 | 18.54 | 17.07 | 2.89 | 14.0 | 0.77 | 0.48 | - | ||
| 2024/10 | 0.25 | 8.0 | 14.95 | 2.6 | 13.66 | 0.72 | 0.51 | - | ||
| 2024/9 | 0.23 | -4.7 | -24.67 | 2.35 | 13.53 | 0.9 | 0.48 | - | ||
| 2024/8 | 0.24 | -44.02 | -14.3 | 2.12 | 20.16 | 0.91 | 0.47 | - | ||
| 2024/7 | 0.43 | 86.8 | 100.15 | 1.88 | 26.74 | 1.0 | 0.43 | 各產品項目皆成長，主係因儀器銷售增加 | ||
| 2024/6 | 0.23 | -30.48 | -12.58 | 1.44 | 14.13 | 0.76 | 0.8 | - | ||
| 2024/5 | 0.33 | 69.93 | 32.69 | 1.21 | 21.19 | 0.75 | 0.81 | - | ||
| 2024/4 | 0.2 | -11.86 | -24.27 | 0.88 | 17.34 | 0.62 | 0.98 | - | ||
| 2024/3 | 0.22 | 10.1 | 8.19 | 0.68 | 39.25 | 0.68 | N/A | - | ||
| 2024/2 | 0.2 | -22.4 | 29.2 | 0.46 | 61.56 | 0.73 | N/A | 各產品項目皆成長，主係因測試收入增加 | ||
| 2024/1 | 0.26 | -2.88 | 100.54 | 0.26 | 100.54 | 0.78 | N/A | 各產品項目皆成長，主係因儀器銷售增加 | ||
| 2023/12 | 0.27 | 6.23 | 6.91 | 2.81 | -12.84 | 0.74 | N/A | - | ||
| 2023/11 | 0.25 | 16.4 | 9.23 | 2.54 | -14.51 | 0.77 | N/A | - | ||
| 2023/10 | 0.22 | -29.23 | -10.31 | 2.29 | -16.51 | 0.8 | N/A | - | ||
| 2023/9 | 0.31 | 8.41 | 11.48 | 2.07 | -17.11 | 0.8 | N/A | - | ||
| 2023/8 | 0.28 | 30.72 | 30.29 | 1.76 | -20.65 | 0.76 | N/A | - | ||
| 2023/7 | 0.22 | -18.41 | -6.45 | 1.48 | -26.15 | 0.73 | N/A | - | ||
| 2023/6 | 0.26 | 5.52 | -34.57 | 1.27 | -28.67 | 0.77 | N/A | - | ||
| 2023/5 | 0.25 | -3.01 | 9.19 | 1.0 | -26.93 | 0.71 | N/A | - | ||
| 2023/4 | 0.26 | 25.92 | -38.47 | 0.75 | -34.21 | 0.62 | N/A | - | ||
| 2023/3 | 0.21 | 31.47 | -37.95 | 0.49 | -31.71 | 0.49 | N/A | - | ||
| 2023/2 | 0.16 | 20.43 | 18.63 | 0.29 | -26.4 | 0.54 | N/A | - | ||
| 2023/1 | 0.13 | -48.22 | -49.49 | 0.13 | -49.49 | 0.61 | N/A | - | ||
| 2022/12 | 0.25 | 8.53 | -39.4 | 3.22 | 2.95 | 0.72 | N/A | - | ||
| 2022/11 | 0.23 | -4.42 | -38.79 | 2.97 | 9.41 | 0.75 | N/A | - | ||
| 2022/10 | 0.24 | -12.02 | -11.04 | 2.74 | 17.19 | 0.73 | N/A | - | ||
| 2022/9 | 0.27 | 26.7 | -6.11 | 2.5 | 20.91 | 0.72 | N/A | - | ||
| 2022/8 | 0.22 | -6.14 | 15.49 | 2.22 | 25.36 | 0.85 | N/A | - | ||
| 2022/7 | 0.23 | -42.93 | -33.33 | 2.0 | 26.53 | 0.87 | N/A | - | ||
| 2022/6 | 0.4 | 76.12 | 35.6 | 1.77 | 43.28 | 1.05 | N/A | - | ||
| 2022/5 | 0.23 | -45.36 | 17.98 | 1.37 | 45.71 | 0.98 | N/A | - | ||
| 2022/4 | 0.42 | 26.98 | 60.37 | 1.14 | 52.96 | 0.88 | N/A | 由於客戶需求增加,致各產品項目皆有所成長,以測試收入成長最多 | ||
| 2022/3 | 0.33 | 151.39 | 81.44 | 0.72 | 48.94 | 0.72 | N/A | 各產品項目皆有成長,主係因儀器及檢測收入增加所致 | ||
| 2022/2 | 0.13 | -48.72 | -28.93 | 0.39 | 29.22 | 0.8 | N/A | - | ||
| 2022/1 | 0.26 | -37.87 | 122.67 | 0.26 | 122.67 | 1.05 | N/A | 各產品項目皆有成長,主係因檢測收入增加所致 | ||
| 2021/12 | 0.41 | 9.62 | 14.62 | 3.13 | -21.46 | 1.06 | N/A | - | ||
| 2021/11 | 0.38 | 38.9 | 2.97 | 2.71 | -25.05 | 0.94 | N/A | - | ||
| 2021/10 | 0.27 | -7.14 | -17.9 | 2.34 | -28.21 | 0.75 | N/A | - | ||
| 2021/9 | 0.29 | 55.86 | 8.27 | 2.06 | -29.38 | 0.83 | N/A | - | ||
| 2021/8 | 0.19 | -45.82 | -45.75 | 1.77 | -33.21 | 0.83 | N/A | - | ||
| 2021/7 | 0.35 | 16.07 | -7.38 | 1.58 | -31.33 | 0.84 | N/A | - | ||
| 2021/6 | 0.3 | 53.23 | 6.58 | 1.24 | -35.96 | 0.0 | N/A | - | ||
| 2021/5 | 0.19 | -25.73 | -54.16 | 0.94 | -43.16 | 0.0 | N/A | 因去年同期儀器設備及試劑耗材銷售額增加,導致本月較去年同期營收減少 |